TABLE 7

Activity, efficacy and toxicity outcomes reported in trials evaluating immune checkpoint inhibitors in thymic epithelial tumours

First author [ref.]PhaseTreatmentnRR/ DCR (%)PFS monthsOS monthsirAEs grade ≥3 (%)
Giaccone [142]IIPembrolizumab40 TC23/764.224.9. (4-year OS: 30%)15
Cho [143]IIPembrolizumab26 TC19/736.114.515.4
7 T29/100NR71.4
Katsuya [145]IINivolumab13 TC0/383.8Nt R15
Heery [144]IAvelumab7 T
1 TC
550/Nt RNt R68

T: Thymoma; TC: Thymic carcinoma; DCR: disease-control rate; PFS: progression-free survival; OS: overall survival; ir-AE: immune related adverse events; NR: not reached; Nt R: not reported. Note: In Giaccone et al. trial, CT-scans were performed every 6 weeks, whereas in Cho et al. trial every 9 weeks.